The investigative oral Factor Xa inhibitor apixaban could prevent strokes among atrial fibrillation patients better than current treatments—and may be able to perform that task without a risk of excessive bleeding.
Two recent publications highlight the long-term safety of these medications, specifically concerning the development of hypomagnesemia and the increased risk of bone fractures.
